Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Page 5 of 15
Aug 26, 2026The agreement includes $400 million in near-term cash, up to $150 million in development and regulatory milestones, and the assumption of milestone obligations linked to Biohaven’s 2022 Knopp Biosciences agreement. For Biohaven, the deal strengthens the balance sheet as investors await data from the Phase 2/3 RISE3 trial in focal epilepsy.
Aug 26, 2026The current reopening looks different from the pandemic-era boom because investors are being more selective and still writing large checks when conviction is high. The main risks, according to Leerink’s Jack Bannister, are preclinical companies rushing out and issuers pushing valuation too far.
Aug 26, 2026The agreement pairs a China-origin immunology asset with U.S. venture backing and a newco structure aimed at ex-China development. For Haisco, it adds another large outbound transaction in a year already marked by deals with Eli Lilly, Nuvectis and AbbVie.
Aug 26, 2026A filing with the Massachusetts Health Policy Commission says Headspace parent OrangeDot proposes to be acquired by Sword Health for cash, with an effective date of Sept. 14. The transaction value was not disclosed, but the move aligns with Sword’s push beyond virtual physical therapy and into mental health.
Aug 25, 2026TME Pharma said it has entered the final evaluation phase of advanced discussions with two potential partners for NOX-A12, a CCL2 inhibitor also known as olaptesed pegol, in brain cancer. For a company that started the year with 2 million euros ($2.3 million) in the bank, the partnering process is not just strategic positioning but a prerequisite for the next clinical step.
Aug 23, 2026Abcuro is using fresh capital to narrow its development strategy around a subgroup that showed a stronger signal in an earlier study. The raise suggests investors still see a regulatory path for ulviprubart despite a setback in a trial that had been expected to support submission.
Aug 22, 2026Capricor’s lead Duchenne muscular dystrophy cell therapy remains under FDA review after a 9-3 advisory committee vote against approval. At the same time, a significant shareholder is arguing that the company’s board has tied too much of Capricor’s capital and future to deramiocel while other programs sit paused.
Aug 22, 2026The combined company will keep the Ambros name, remain based in San Diego and be led by current Ambros CEO Jay Hagan. Its lead asset, neridronate, is in an ongoing Phase 3 trial in complex regional pain syndrome type 1 and already holds breakthrough therapy, fast track and orphan drug designations from the FDA.
Aug 20, 2026Scribe raised an upsized $150 million and has climbed 43% from its first-day price of $21.50 to $31.05 by Wednesday’s close, compared with a 12% gain in the XBI over the last month. The company is heading into Phase 1 in Australia with STX-1150, a PCSK9-targeting epigenetic silencer that investors will begin to judge on interim patient data in the first half of next year.
Aug 20, 2026The argument is that investors and regulators are still willing to back pediatric rare cancer programs when biology, endpoints, and patient need are tightly aligned. The February renewal of the pediatric rare disease priority review voucher, after a lapse at the end of 2024, is presented as a key policy support for that thesis.
Aug 18, 2026Quarterly biopharma venture capital deployment topped $10 billion last month for the third time since early 2022, and VC-backed exits reached a collective $34.4 billion. PitchBook argues that the lagged effect of that capital should begin showing up in pharma services demand in late 2026 or early 2027.
Aug 17, 2026Two business signals emerged from STAT’s reporting on health care finance. UnitedHealth disclosed an IRS investigation that could raise its taxable income for 2017 through 2020 and potentially later years, while a separate report showed physician practice management deals are on track to run at about half last year’s level as state oversight expands.
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.